Credit Suisse AG increased its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) by 6.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 185,980 shares of the company’s stock after acquiring an additional 11,446 shares during the period. Credit Suisse AG owned about 0.11% of HUTCHMED worth $1,648,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of HCM. Goldman Sachs Group Inc. lifted its stake in HUTCHMED by 1,096.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 3,913,287 shares of the company’s stock worth $49,464,000 after acquiring an additional 3,586,271 shares in the last quarter. M&G Investment Management Ltd. increased its holdings in HUTCHMED by 22.9% during the 3rd quarter. M&G Investment Management Ltd. now owns 8,577,437 shares of the company’s stock worth $77,197,000 after purchasing an additional 1,600,209 shares during the period. Bellevue Group AG increased its holdings in HUTCHMED by 62.6% during the 1st quarter. Bellevue Group AG now owns 1,750,690 shares of the company’s stock worth $33,123,000 after purchasing an additional 673,820 shares during the period. Allianz Asset Management GmbH increased its holdings in HUTCHMED by 38.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 1,761,689 shares of the company’s stock worth $15,609,000 after purchasing an additional 488,185 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in HUTCHMED during the 2nd quarter worth about $5,266,000. Institutional investors and hedge funds own 22.14% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald restated an “overweight” rating on shares of HUTCHMED in a report on Wednesday, March 1st.
HUTCHMED Trading Down 2.7 %
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating).
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.